Index Bio is pleased to announce the addition of Dr. David Acheson, President & CEO of the Acheson Group, to the company’s distinguished team of advisors. Dr. Acheson brings decades of experience as one of the world’s foremost food safety authorities.
About Dr. David Acheson
Dr. David Acheson is widely recognized as a global leader in food safety, having served as:
- Former Associate Commissioner for Foods at the FDA
- Chief Medical Officer at the USDA Food Safety and Inspection Service
- Former Director of the FDA’s Center for Food Safety and Applied Nutrition (CFSAN)
- Founder and CEO of The Acheson Group, a leading food safety consulting firm
His deep expertise in regulatory affairs, food safety science, and industry practices makes him an invaluable addition to Index Bio’ advisory board.
Dr. Acheson’s Perspective on BioTag Technology
“BioTags® present the opportunity to reduce the scope of recalls and absolve unaffected products from allegations of contamination,” said Dr. Acheson. “This could open entirely new product categories to recall and contamination insurance.”
This perspective is grounded in Dr. Acheson’s extensive work with food companies navigating the costly and complex world of food recalls. The ability to precisely trace contamination paths — and equally importantly, to demonstrate where contamination did NOT go — is a powerful capability that BioTag technology uniquely enables.
Strategic Value for Index Bio
Dr. Acheson’s addition to the advisory team will support Index Bio in:
- Navigating complex regulatory landscapes in North America and internationally
- Building credibility with large food manufacturers evaluating the technology
- Shaping the commercial strategy for BioTag deployments
- Advising on industry best practices and evolving regulatory requirements
A Growing Advisory Team
This announcement reflects Index Bio’ commitment to building a world-class advisory team that combines scientific expertise with deep industry experience. The company continues to attract thought leaders who recognize the transformational potential of BioTag technology.